

STATUS OF CLAIMS

IN THE CLAIMS:

1. (Previously Presented). A method for treating gastric acid disorders comprising the step of administering to a patient in need of such treatment a therapeutically effective amount of at least one non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier; wherein said pharmaceutically acceptable carrier comprises an equimolar ratio of a bicarbonate salt of a Group IA metals and a carbonate salt of a Group IA metal where the Group IA metals is chosen from the Periodic Table of Elements.
2. (Original). The method of claim 1 wherein said Group IA metal of said bicarbonate salt is sodium.
3. (Original). The method of claim 1 wherein said Group IA metal of said carbonate salt is sodium.
4. (Original). The method of claim 1 wherein said Group IA metal of said bicarbonate salt is potassium.
5. (Original). The method of claim 1 wherein said Group IA metal of said carbonate salt is potassium.
6. (Original). The method of claim 1 wherein said non-enteric coated proton pump inhibitor is a substituted benzimidazole or pharmaceutically acceptable salt thereof.
7. (Original). The method of claim 6 wherein said substituted benzimidazole is lansoprazole or a pharmaceutically acceptable salt thereof.
8. (Cancelled).

9. (Original). The method of claim 2 wherein said bicarbonate salt of said Group IA metal is sodium bicarbonate.

10. (Original). The method of claim 3 wherein said carbonate salt of said Group IA metal is sodium carbonate.

11. (Original). The method of claim 9 wherein said pharmaceutically acceptable carrier contains from about 125mg to about 1000mg of sodium bicarbonate.

12. (Original). The method claim of claim 10 wherein said pharmaceutically acceptable carrier contains from about 125mg to about 1000mg sodium carbonate.

13. (Previously Presented). A method for treating gastric acid disorders comprising the step of administering to a patient in need of such treatment a therapeutically effective amount of non-enteric coated lansoprazole or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier;

wherein said pharmaceutically acceptable carrier comprises an equimolar ratio of sodium carbonate to sodium bicarbonate.

14. (Original). The method of claim 13 wherein said pharmaceutically acceptable carrier contains from about 125mg to about 1000mg of sodium carbonate, and from about 125mg to about 1000mg of sodium bicarbonate.

15. (Previously Amended). A pharmaceutical composition comprising:
at least one non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier;

wherein said pharmaceutically acceptable carrier comprises an equimolar ratio of bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal, where the Group IA metal is chosen from the Periodic Table of Elements.

16. (Original). The composition of Claim 15 wherein said Group IA metal of said bicarbonate salt is sodium.

17. (Original). The composition of claim 15 wherein said Group IA metal of said carbonate salt is sodium.

18. (Original). The composition of claim 15 wherein said Group IA metal of said bicarbonate salt is potassium.

19. (Original). The composition of claim 15 wherein said Group IA metal of said carbonate salt is potassium.

20. (Original). The composition of claim 15 wherein said non-enteric coated proton pump inhibitor is a substituted benzimidazole or pharmaceutically acceptable salt thereof.

21. (Original). The composition of claim 20 wherein said benzimidazole is lansoprazole or a pharmaceutically acceptable salt thereof.

22. (Cancelled).

23. (Original). The composition of claim 16 wherein said bicarbonate salt of said Group IA metal is sodium bicarbonate.

24. (Original). The composition of claim 17 wherein said carbonate salt of said Group IA metal is sodium carbonate.

25. (Original). The composition of claim 15 wherein said pharmaceutically acceptable carrier contains from about 125 mg to about 1000mg of sodium carbonate and

from about 125mg to about 1000mg of sodium bicarbonate.

26. (Previously Presented). A non-enteric coated lansoprazole composition comprising:

- a) lansoprazole without enteric coating;
- b) an equimolar ratio of a bicarbonate salt of a Group IA metal; and

a carbonate salt of a Group IA metal wherein the Group 1A metal is chosen from the Periodic Table of Elements.

27. (Original). The composition of claim 26 wherein said bicarbonate salt of said Group IA metal is sodium bicarbonate.

28. (Original). The composition of claim 26 wherein said carbonate salt of said Group IA metal is sodium carbonate.

29. (Original). The composition of claim 26 having from about 125mg to about 1000mg of sodium carbonate, and from about 125mg to about 1000mg of sodium bicarbonate.

30. (Previously Presented). A pharmaceutical composition comprising:
at least one non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier;
wherein said pharmaceutically acceptable carrier comprises an equimolar ratio of sodium bicarbonate and sodium carbonate.

31. (Previously Presented). The composition of claim 30 wherein the proton pump inhibitor is lansoprazole.

32. (Previously Presented). The composition of claim 30 having from about 125mg to about 1000mg of sodium carbonate, and from about 125mg to about 1000mg of

sodium bicarbonate.

33. (Previously Presented). A method for treating gastric disorders comprising the step of administering to a patient in need of such treatment a therapeutically effective amount of the composition of claim 30.

34. (Previously Presented). The method of claim 1 wherein the proton pump inhibitor is selected from the group consisting of: omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole, and leminoprazole.

35. (Previously Presented). The composition of claim 15 wherein the proton pump inhibitor is selected from the group consisting of: omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole, and leminoprazole.

36. (Previously Presented). The composition of claim 30 wherein the proton pump inhibitor is selected from the group consisting of: omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole, and leminoprazole.